Yanyu Jiang

No. 24 Fu Kang Road
Changhongjie, 300192, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

SLC43A2-mediated immune cell infiltration: a potential therapeutic target in acute myeloid leukemia.

SLC43A2-mediated immune cell infiltration: a potential therapeutic target in acute myeloid leukemia.

Journal: Frontiers in immunology

Published: June 28, 2025

A novel malnutrition assessment model predicts the inflammatory storm of relapsed/refractory acute myeloid leukemia following C-type lectin-like molecule-1 chimeric antigen receptor T therapy.

A novel malnutrition assessment model predicts the inflammatory storm of relapsed/refractory acute myeloid leukemia following C-type lectin-like molecule-1 chimeric antigen receptor T therapy.

Journal: Frontiers in nutrition

Published: May 13, 2025

Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report.

Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report.

Journal: Blood advances

Published: October 03, 2024

Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.

Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.

Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University

Published: February 11, 2022

A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.

A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.

Journal: Leukemia & lymphoma

Published: February 02, 2022

Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.

Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.

Journal: Hematological oncology

Published: November 25, 2021

Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.

Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.

Journal: Frontiers in oncology

Published: June 16, 2021

Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia.

Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia.

Journal: Journal of hematology & oncology

Published: May 31, 2021

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk.

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk.

Journal: Frontiers in oncology

Published: May 06, 2021

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.

Journal: OncoTargets and therapy

Published: April 09, 2021

ALS3 Expression as an Indicator for Candida albicans Biofilm Formation and Drug Resistance.

ALS3 Expression as an Indicator for Candida albicans Biofilm Formation and Drug Resistance.

Journal: Frontiers in microbiology

Published: January 18, 2021

Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines in vitro and in vivo.

Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines in vitro and in vivo.

Journal: American journal of cancer research

Published: July 07, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026